Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus ALTRENO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUTANE versus ALTRENO.
ACCUTANE vs ALTRENO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
ALTRENO is not a recognized drug. No data available.
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Category C
Category C
Retinoid
Retinoid